Main Products/ Pipelines & Platforms
The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal cream for the treatment of Atopic Dermatitis (AD), plaque psoriasis and wound healing. The efficacy and safety of GM-XANTHO in patients with mild-to-moderate atopic dermatitis have been evaluated in a completed double-blinded, placebo-controlled Phase IIa clinical trial. We are now preparing to advance to a Phase IIb clinical trial.
GM-XANTHO has obtained IND approvals and completed Phase I/IIa trials in both Taiwan and the United States. It is available for out-licensing, including rights for drug development and commercialization.
Business Interests
Out-Licensing, Collaborative R&D, CDMO, CRO, Clinical Trial Collaboration, Co-Development
Contact Info
William Liang
Clinical Project Manager
+886-2-2655-7790#10
william.liang@xanthobio.com; business@xanthobio.com